Christopher Ballantyne
University of Virginia Medical Center, University of Virginia, Mayo Clinic in Florida
Papers
3
Total Citations
18
H-Index
2
About
Christopher Ballantyne is a health services researcher and urologic oncologist whose work centers on the comparative effectiveness and cost-efficiency of minimally invasive treatments for kidney cancer and stone disease. His major contributions lie in rigorously comparing the economic and clinical outcomes of percutaneous microwave ablation (MWA) versus robotic-assisted partial nephrectomy for small renal masses. In his most-cited paper (2022, 11 citations), Ballantyne demonstrated that MWA offers a significantly lower perioperative cost profile while maintaining comparable oncologic efficacy, providing crucial evidence for value-based treatment decisions. His 2021 study (6 citations) further substantiated these findings through a detailed retrospective cohort analysis, cementing his reputation as a leading voice in cost-effectiveness research for localized renal masses. Most recently, Ballantyne has advanced surgical innovation by evaluating robotic-assisted electromagnetic guidance for percutaneous nephrolithotomy access, showing that this technology improves success rates for both novices and experts alike (2025). His work directly informs clinical guidelines and resource allocation, helping surgeons and hospitals balance patient outcomes with economic realities. Ballantyne’s research is essential reading for clinicians and policymakers navigating the evolving landscape of urologic oncology and stone disease management.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3